Skip to content

Zevra Therapeutics, Inc. ZVRA Balance Sheet Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$95.6M+53.2%$62.41M+14.6%$54.44M+14.1%$47.71M+27.8%$37.34M+10.5%
$105.02M-18.3%$128.61M-11.3%$145.07M-6.3%$154.9M+512%$25.29M-29.2%
$22.1M-5.0%$23.26M+38.1%$16.84M-7.8%$18.27M+44.8%$12.62M+20.1%
$2.38M-81.7%$13M-43.8%$23.12M-25.8%$31.15M-23.2%$40.57M-4.3%
$7K
$863K
$1.44M
$4.94M-29.4%$7M-5.4%$7.4M+70.0%$4.35M+15.6%$3.77M-7.1%
$229.97M+3.1%$223.01M-0.9%$225.12M-0.5%$226.34M+177%$81.57M-5.2%
$430K-12.1%$489K+0.2%$488K-18.5%$599K+41.9%$422K+18.5%
13.1%+0.1%13%+0.1%12.9%+0.3%12.6%-163,599,987%163,600,000%+97,900,000%
$4.7M0.0%$4.7M0.0%$4.7M0.0%$4.7M0.0%$4.7M0.0%
$6.11M-4.9%$6.42M-4.7%$6.74M-4.5%$7.05M-89.5%$67.38M-2.3%
$143K0.0%$143K-6.5%$153K-30.5%$220K-24.9%$293K-23.7%
$82.6M
$36.1M-24.6%$47.88M+54.9%$30.9M+105%$15.1M
$278.58M-2.2%$284.73M+5.4%$270.12M+5.4%$256.28M+48.4%$172.71M-3.0%
$11.69M+0.8%$11.6M+4.8%$11.07M-30.1%$15.84M-11.1%$17.82M-30.0%
$1.41M+3.4%$1.36M-84.8%$8.99M+30.9%$6.87M+102%$3.4M+50.5%
$406K-3.1%$419K-5.0%$441K-16.0%$525K-10.9%$589K+40.2%
$0
$20.35M+48.5%$13.71M-21.5%$17.46M
$47.03M+19.7%$39.28M+50.4%$26.11M-9.4%$28.83M+6.9%$26.98M-20.8%
$0-100%$61.93M+1.0%$61.31M+1.0%$60.69M+1.0%$60.09M+1.0%
$741K-13.7%$859K-11.1%$966K-8.8%$1.06M-8.5%$1.16M+211%
$1.15M-10.3%$1.28M-9.2%$1.41M-11.2%$1.58M-9.3%$1.75M+121%
$1.86M+8.5%$1.71M-57.1%$4M+20.5%$3.32M-32.0%$4.88M+5.3%
$8.16M-26.6%$11.12M-91.9%$136.95M-1.5%$139.05M+5.6%$131.69M-4.9%
$0
$6K0.0%$6K0.0%$6K0.0%$6K+20.0%$5K0.0%
$602.75M+2.4%$588.46M+1.3%$580.78M+2.9%$564.32M+0.7%$560.47M+0.9%
-$384.17M+9.0%-$422.06M+2.8%-$434.23M-0.1%-$433.68M+14.7%-$508.39M-0.6%
-$1.8M-135%-$764K+68.4%-$2.42M+0.5%-$2.43M-2,861%-$82K-113%
$10.98M0.0%$10.98M0.0%$10.98M0.0%$10.98M0.0%$10.98M0.0%
$205.8M+33.1%$154.66M+16.1%$133.17M+13.6%$117.23M+186%$41.02M+3.4%
$278.58M-2.2%$284.73M+5.4%$270.12M+5.4%$256.28M+48.4%$172.71M-3.0%
$0
$0
$95.6M+53.2%$62.41M+14.6%$54.44M+14.1%$47.71M+27.8%$37.34M
$105.02M-18.3%$128.61M-11.3%$145.07M-6.3%$154.9M+512%$25.29M-29.2%
$143K0.0%$143K-6.5%$153K-30.5%$220K-24.9%$293K-23.7%
$2M
$2M
$2M
$2M
$1.09M-10.3%$1.21M-9.3%$1.34M-10.6%$1.5M-8.6%$1.64M+149%
$36.15M-24.5%$47.88M+55.1%$30.87M+105%$15.09M
$6.11M-4.9%$6.42M-4.7%$6.74M-4.5%$7.05M-89.5%$67.38M-2.3%
$1.09M-10.3%$1.21M-9.3%$1.34M-10.6%$1.5M-8.6%$1.64M+149%
$143K0.0%$143K-6.5%$153K-30.5%$220K-24.9%$293K-23.7%
$1.09M-10.3%$1.21M-9.3%$1.34M-10.6%$1.5M-8.6%$1.64M+149%
$143K0.0%$143K-6.5%$153K-30.5%$220K-24.9%$293K-23.7%
$11.69M+0.8%$11.6M+4.8%$11.07M-30.1%$15.84M-11.1%$17.82M-30.0%
$13.17M+8.1%$12.19M+117%$5.61M+0.2%$5.6M+8.4%$5.17M+3.6%
$1.41M+3.4%$1.36M-84.8%$8.99M+30.9%$6.87M+102%$3.4M+50.5%
$1.15M-98.2%$63.21M+0.8%$62.72M+0.7%$62.28M+0.7%$61.84M+2.6%
$0.00
60.7M
10M
0
0
$602.75M+2.4%$588.46M+1.3%$580.78M+2.9%$564.32M+0.7%$560.47M+0.9%
$0
$10.98M0.0%$10.98M0.0%$10.98M0.0%$10.98M0.0%$10.98M0.0%
$0.00
18.6M
$6.87M-2.2%$7.03M-59.8%$17.46M
$0
$95.6M+53.2%$62.41M+14.6%$54.44M+14.1%$47.71M+27.8%$37.34M
$18.62M
$0
$250M
$60.69M
$59.11M+4.0%$56.85M+1.1%$56.22M
$0
$6.8M-29.0%$9.58M-30.4%$13.77M-12.9%$15.81M+21.3%$13.03M-26.8%
$9.48M-2.2%$9.69M-27.3%$13.34M+12.4%$11.86M+26.3%$9.39M+22.7%
$2M
$7K
$82.6M
$0.13
$0
$10M
$0
$0

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Zevra Therapeutics, Inc.'s total assets?
Zevra Therapeutics, Inc. (ZVRA) holds $278.6M in total assets, up 61.3% year over year.
How much debt does Zevra Therapeutics, Inc. have?
Zevra Therapeutics, Inc. carries $1.1M in total debt against $205.8M of shareholders' equity, a debt-to-equity ratio of 0.01.
How much cash does Zevra Therapeutics, Inc. have?
Zevra Therapeutics, Inc. holds $95.6M in cash and equivalents.
Can Zevra Therapeutics, Inc. cover its short-term obligations?
Its current ratio is 4.89 — current assets exceed current liabilities.
Where does Zevra Therapeutics, Inc.'s balance sheet data come from?
Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.